Logo

ActivX, Following Acquisition, Becomes Subsidiary of Kyorin Pharmaceutical

Feb 02, 2005

NEW YORK, Feb. 2 (GenomeWeb News) - Kyorin Pharmaceutical of Tokyohas completed its acquisition of ActivX Biosciences, La Jolla, Calif.-based ActivX said today.

 

ActivX became a wholly owned subsidiary of Kyorin, serving as the company's USdrug-discovery and development center.

 

The $21 million acquisition was first announced in December.

Breaking News
The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.